This is the authors' abstract. We don't add key points for this paper.
CBD at low doses corresponding to plasma concentrations observed physiologically inhibits or desensitizes neuronal TRPV1 signalling by inhibiting the adenylyl cyclase - cAMP pathway, which is essential for maintaining TRPV1 phosphorylation and sensitization. CBD also facilitated calcineurin-mediated TRPV1 inhibition. These mechanisms may underlie nociceptor desensitization and the therapeutic effect of CBD in animal models and patients with acute and chronic pain.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Anand et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: